1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Scleroderma Research Foundation, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Clinical Study for Conquering Scleroderma Amlitelimab, BI 1015550 (Nerandomilast), Placebo - Interstitial Lung Disease Due to Systemic Disease, Scleroderma | Phase 2 | Recruiting | Scleroderma Research Foundation, Inc. | 400 | 2024-04-15 | 2026-08-18 |
Lung Diseases, Interstitial (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1)
BI 1015550 (1)
United States (1)
Kevin O'Shea (1)